Loading stock data…
ADMA
$7.95-0.22 (-2.69%)
Market OpenUpdated 2:41 PM EDT
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ADMA Biologics, Inc. in the Healthcare sector is trading at $7.95. The stock is currently near its 52-week low of $7.21, remaining 49.0% below its 200-day moving average. Technical signals show oversold RSI of 17 and bearish MACD signal, explaining why ADMA maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 17) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.95
Potential Upside
46.6%
Whystock Fair Value$11.65
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$16.75+110.7%
Range$12.00 – $20.00
Fundamentals
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.61B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
18.25
Beta
Defensive asset. Lower volatility than the S&P 500.
0.82
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
43.77%
Volume
Today's trading volume
4.34M
Recent News
New Strong Sell Stocks for May 11th
ADMA, APTV and ASTE have been added to the Zacks Rank #5 (Strong Sell) List on May 11th, 2026.
How The ADMA Biologics (ADMA) Story Is Shifting As Targets And Scrutiny Tighten
ADMA Biologics is now being modeled with a trimmed fair value estimate, moving from US$27.25 to about US$18.33, a reduction of roughly one third in the central price target. That reset lines up with recent Street commentary that mixes optimism about ADMA’s setup with fresh caution around execution and valuation, which is showing up directly in those lower targets. As you read on, you will see how this changing narrative fits together and what to monitor in order to keep up with the next round...
ADMA Q1 EPS Jumps 73% Y/Y, Revenues Slip, 2026 View Down
ADMA cuts its 2026 outlook after Q1 revenues slip amid IG market pressure, though Asceniv demand and margins stay strong.
ADMA Biologics, Inc. Q1 2026 Earnings Call Summary
Moby summary of ADMA Biologics, Inc.'s Q1 2026 earnings call
High Growth Tech Stocks to Watch in the US May 2026
The United States market has shown a robust performance, climbing 3.2% in the last week and up 31% over the past year, with earnings forecasted to grow by 16% annually. In such a dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and scalability to capitalize on these favorable market conditions.